Abstract:44 Background: Immune checkpoint inhibitors (ICIs) have improved the therapeutic prospects in advanced gastrointestinal tumors. The PD-L1 expression has become one of predictive biomarkers for immunotherapy and used in treatment, but there are still some drawbacks. The aim of this study was to investigate the changes in peripheral blood T-lymphocyte subsets, IL-6 levels before and after treatment with ICIs and clinical significance. Methods: 70 patients with advanced gastrointestinal tumors who were hospitalized in Shaanxi Provincial People's Hospital from January 2020 to December 2022 were selected. 30 healthy patients were selected as controls. PD-L1 was detected by immunohistochemistry. Patients were treated with ICIs (sintilimab or pembrolizumab). 1 day before treatment, 20 days after the end of the 4 cycles of treatment, peripheral venous blood was collected and CT or MRI was performed to evaluate the therapeutic effect. Complete response (CR), partial response (PR), and stable disease (SD) were classified as immune response group, and progressive disease (PD) was classified as immune non-response group. To evaluate the effects of ICIs on the levels of T-lymphocyte subsets (Percentage of CD3 + T cells, percentage of CD4 + T cells, percentage of CD8 + T cells, CD4 + /CD8 + , CD3 + T cells, CD4 + T cells, CD8 + T cells) and IL-6. Results: Compared to controls, CD3 + T cells, CD4 + T cells, CD8 + T cells and CD4 + /CD8 + were significantly lower ( P<0.05). After 4 cycles of immunotherapy, the CD3 + T cells, CD4 + T cells, CD8 + T cells, and CD4 + /CD8 + levels were significantly higher ( P<0.05), and IL-6 levels were lower ( P<0.05). After 4 cycles of treatment, 48 cases were divided in the immune response group and 22 cases in the immune non-response group, with a treatment efficiency of 68.6%. In the immune response group compared to the immune non-response group, the levels of percentage of CD4 + T cells, CD4 + /CD8 + , CD3 + T cells and CD4 + T cells were significantly higher ( P<0.05), while the percentage of CD8 + T cells level was lower ( P<0.05). The percentage of CD4 + T cells, CD4 + /CD8 + , CD3 + T cells, CD4 + T cells and CD8 + T cells were significantly higher ( P<0.05) in the immune response group after 4 cycles of immunotherapy, while the percentage of CD8 + T cells level was lower ( P<0.05) compared to before immunotherapy. The percentage of CD4 + T cells and CD4 + /CD8 + were significantly lower ( P<0.05), the percentage of CD8 + T cells and CD8 + T cells were higher ( P<0.05) in the immune non-response group compared to before immunotherapy. In the immune response group, the percentage of CD4 + T cells was higher in the PD-L1 high expression groups (≥ 50%) compared to the PD-L1 low expression groups (< 50%) ( P<0.05). Conclusions: PD-1 inhibitors can affect the distribution of immune cells such as T-lymphocyte subsets in patients with advanced gastrointestinal tumors and improve the immune status of patients.

Predictive value of CD4+/CD8+ratio after treatment for efficacy of immune check-point inhibitor combined with pingxiao capsule in the treatment of digestive system malignant tumors

Intratumoral CD8+ T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: a retrospective cohort study

A Novel Immunogenic Cell Death-Related Genes Signature for Predicting Prognosis, Immune Landscape and Immunotherapy Effect in Hepatocellular Carcinoma.

Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients

Early Change In Peripheral Cd4(+)T Cells Associated With Clinical Outcomes Of Immunotherapy In Gastrointestinal Cancer

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Efficacy of PD-1 Inhibitors in the Treatment of Advanced Gastrointestinal Tumors and the Effect on T-lymphocyte Subsets and IL-6 Levels in Patients.

Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

Predictive response and outcome of peripheral CD4+ T cell subpopulations to combined immunotherapy and chemotherapy in advanced gastric cancer patients

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

Expression Pattern and Prognostic Value of CTLA-4, CD86, and Tumor-Infiltrating Lymphocytes in Rectal Cancer after Neoadjuvant Chemo(radio)therapy.

[Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes Ratio to Predict the Response and Prognosis of Immunotherapy to Advanced Lung Cancer]

The Association between Cd8+ Tumor-Infiltrating Lymphocytes and Response to Cancer Immunotherapy: A Systematic Review and Meta-Analysis

The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis

P3.04-04 Prognostic Value of MHC-I, PD-L1 and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer

Efficacy of Integrated Immune Ratio Associated with Tumor Growth and Prognosis in Pancreatic Cancer

Clinical and molecular mechanisms for predicting the efficacy of immunotherapy for hepatocellular carcinoma based on gut microbiome.

Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy

Clinical Significance of Peripheral T-cell Receptor Repertoire Profiling and Individualized Nomograms in Patients with Gastrointestinal Cancer Treated with Anti-Programmed Death 1 Antibody.

Prognostic Value Of Tumor Infiltrating Lymphocytes Combined With Pd-L1 Expression For Patients With Solitary Colorectal Cancer Liver Metastasis